Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FLT3 mutations in myeloid sarcoma.

M Ali Ansari-Lari1, Ching-Fen Yang, Rima Tinawi-Aljundi

  • 1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

British Journal of Haematology
|September 9, 2004
PubMed
Summary

Myeloid sarcoma, a tumor outside the bone marrow, can have Fms-like tyrosine kinase 3 (FLT3) mutations. Analyzing these mutations in the sarcoma itself is crucial due to potential differences from leukemia mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking perioperative chemotherapy in older adults with gastric cancer: a retrospective cohort study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Prognostic impact of germline and somatic variants in lymphoma-associated haemophagocytic lymphohistiocytosis.

British journal of haematology·2026
Same author

Rethinking Perioperative Care in Older Adults: A Plea for Specialization.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

Complex Surgical Decision-Making in a Nonagenarian With Long-Term Cancer Survivorship.

Journal of the American Geriatrics Society·2026
Same author

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Blood advances·2026
Same author

From frailty to decision: impact of comprehensive geriatric assessment on surgical planning and outcomes in older adults with gastrointestinal malignancies.

Frontiers in oncology·2026

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myeloid sarcoma is an extramedullary tumor often associated with acute myeloid leukemia (AML) or myeloproliferative disorders.
  • Fms-like tyrosine kinase 3 (FLT3) mutations, specifically internal tandem duplications (ITD) and D835 point mutations, are common in AML.
  • Understanding FLT3 mutation status in myeloid sarcoma is critical for potential targeted therapies.

Purpose of the Study:

  • To investigate the frequency and characteristics of FLT3 ITD and D835 mutations in myeloid sarcoma specimens.
  • To assess the concordance of FLT3 mutational status between myeloid sarcoma and matched leukemia samples.
  • To evaluate the therapeutic implications of FLT3 mutations in myeloid sarcoma.

Main Methods:

  • Analysis of 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations.

Related Experiment Videos

  • Sequencing to detect internal tandem duplications (ITD) and point mutations in the FLT3 gene.
  • Comparison of FLT3 mutation status between myeloid sarcoma and corresponding leukemia samples.

    • Main Results:

    • FLT3 ITD mutations were identified in 15% (3 of 20) of myeloid sarcoma cases; no D835 mutations were found.
    • ITD insert sizes varied from 33 to 198 base pairs, representing 20-40% of FLT3 alleles.
    • Discordance in FLT3 ITD status was observed between leukemia and myeloid sarcoma in two cases, including one with differing status at diagnosis and relapse.

    Conclusions:

    • FLT3 ITD mutations occur in a subset of myeloid sarcomas.
    • Small molecule inhibitors targeting FLT3 may offer therapeutic potential for myeloid sarcomas with FLT3 mutations.
    • Direct analysis of FLT3 mutations within myeloid sarcoma tissue is essential due to potential discordance with leukemia mutation status.